Our Beacon® Platforms and Technology
Nona Biosciences has developed cutting-edge high-throughput screening platforms to expedite antibody discovery.
Since early 2019, our scientific team has established a single B cell cloning (SBC) platform using Berkeley Lights Beacon® Optofluidic technology. We have accumulated substantial expertise in Beacon® and SBC through dozens of antibody discovery projects. Leveraging optimized murine plasma cell enrichment methods, robust and reliable in-chip assay development process, highly efficient single cell sequencing technology, and high-throughput recombinant antibody screening techniques, we’ve successfully applied our SBC platform to more than 50 different antibody generation projects with shortened screening timeline and increased sequence diversity.
We’ve also optimized an innovative high-throughput technology for rapid direct cloning and production of fully human HCAbs from B cells of HCAb Harbour Mice®, which was originally developed in 2016 (Drabek, D. et al. Frontiers in Immunology 7, 3–12 (2016)). This technology facilitates the production of fully human HCAbs in 96-well plates and expedites the process of functional screening.
Despite the capacity of these high-throughput technologies to rapidly screen tens of thousands of B cells and provide a wide array of sequences we are highly motivated to embrace new technologies, such as artificial intelligence (AI), to further increase the screening efficiency and sequence diversity. Through the integration of next-generation sequencing and machine learning, we can explore a more extensive sequence space and uncover sequences that cannot be easily identified by other screening methods.
Welcome to the forefront of biotherapeutic innovation, where Nona Biosciences leverages advanced antibody-LNP conjugation techniques to revolutionize targeted delivery systems. Our state-of-the-art technology enhances the precision and efficacy of therapeutic cargo delivery, offering groundbreaking solutions for various medical applications.
Welcome to the forefront of biotherapeutic innovation, where Nona Biosciences leverages advanced antibody-LNP conjugation techniques to revolutionize targeted delivery systems. Our state-of-the-art technology enhances the precision and efficacy of therapeutic cargo delivery, offering groundbreaking solutions for various medical applications.
Each 20K OptoSelect chip has 20,000 individual NanoPen chambers and can separate and screen up to 20,000 cells within a single run.
With real-time fluorescent microscopy technology, different assays could be performed in-chip for plasma cell screening, including:
All these advantages make SBC platform to become highly efficient and robust antibody discovery platform.
Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.
Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.
At Nona Biosciences, we explore both passive and active targeting strategies to optimize nanoparticle delivery systems. Our focus is on tissue-specific and cell-specific delivery to achieve unparalleled precision in reprogramming cells in vivo.
Tailoring delivery strategies to meet diverse therapeutic objectives.
Essential for precise in vivo cell reprogramming.
At Nona Biosciences, we explore both passive and active targeting strategies to optimize nanoparticle delivery systems. Our focus is on tissue-specific and cell-specific delivery to achieve unparalleled precision in reprogramming cells in vivo.
Tailoring delivery strategies to meet diverse therapeutic objectives.
Essential for precise in vivo cell reprogramming.
Each 20K OptoSelect chip has 20,000 individual NanoPen chambers and can separate and screen up to 20,000 cells within a single run.
With real-time fluorescent microscopy technology, different assays could be performed in-chip for plasma cell screening, including:
All these advantages make SBC platform to become highly efficient and robust antibody discovery platform.
Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.
Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.
Nona’s innovative LNP conjugation with specific antibodies significantly improves endocytosis in targeted cells. The advancement underscores our commitment to enhancing therapeutic delivery and efficacy.
IgG-LNP conjugation
HCAb-LNP conjugation
VHH-LNP conjugation
Fig. Various antibody formats for Antibody-LNP conjugate
HCAb-LNP conjugation
Fig. The LNP conjugated with anti-TAA HCAb improves the delivery to TAA+ tumors and increases Fluc expression in tumors
VHH-LNP conjugation
Fig. Anti-TAA VH site-specific conjugation to LNP can improve endocytosis on TAA+ tumor cells
Nona Biosciences is dedicated to advancing biotherapeutic innovation through robust technology platforms:
Efficiently deliver genetic material to target cells.
Precisely target and deliver therapeutic agents.
Accelerate the development of highly specific CAR-T therapies.
Leveraging Harbour Mice® platforms and expertise, Nona provides a complete solution for fully human H2L2, HCAb, and bi/multi-specific antibody discovery, including antigen preparations, immunization, antibody screening, engineering, and functional evaluation.
mRNA-encoding biologics are revolutionizing the field of medicine by harnessing the power of mRNA technology. Our innovative approach leverages the Harbour HCAb Mice® platform to develop HCAbs encoded by mRNA and delivered via LNP. This cutting-edge technology provides a versatile and powerful method for creating therapeutic agents with enhanced efficacy and specificity.
Each 20K OptoSelect chip has 20,000 individual NanoPen chambers and can separate and screen up to 20,000 cells within a single run.
With real-time fluorescent microscopy technology, different assays could be performed in-chip for plasma cell screening, including:
All these advantages make SBC platform to become highly efficient and robust antibody discovery platform.
Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.
Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.
The HCAb TAA x CD3 mRNA-LNP demonstrates significant cytotoxic effects on TAA-expressing target cells.
The HCAb TAA x CD3 mRNA-LNP demonstrates significant cytotoxic effects on TAA-expressing target cells.
The TAA x CD3 mRNA-LNP targets TAA-positive cells specifically, minimizing off-target effects and underscoring the precision of the mRNA-LNP therapy.
The TAA x CD3 mRNA-LNP targets TAA-positive cells specifically, minimizing off-target effects and underscoring the precision of the mRNA-LNP therapy.
The TAA x CD3 mRNA-LNP displays a unique killing pattern compared to traditional recombinant proteins.
The TAA x CD3 mRNA-LNP displays a unique killing pattern compared to traditional recombinant proteins.
The TAA x CD3 mRNA-LNP significantly reduces tumor volume in vivo in a dose-dependent manner.
The fully human HCAb-based mRNA-LNP platform, developed using Harbour HCAb Mice®, offers a promising approach for designing highly specific and potent biologics. With precise targeting and effective killing patterns, Nona Biosciences’ mRNA-LNP platform demonstrates potent anti-tumor efficacy, positioning it at the forefront of next-gen therapies.
The TAA x CD3 mRNA-LNP significantly reduces tumor volume in vivo in a dose-dependent manner.
The fully human HCAb-based mRNA-LNP platform, developed using Harbour HCAb Mice®, offers a promising approach for designing highly specific and potent biologics. With precise targeting and effective killing patterns, Nona Biosciences’ mRNA-LNP platform demonstrates potent anti-tumor efficacy, positioning it at the forefront of next-gen therapies.
Nona offers a variety of bioconjugation technologies such as lysine/cysteine-based conjugation with optimized DAR value and optimization of reaction conditions. Our proprietary DAR2 site-specific conjugation and linker-payload library include the majority of classical linker-payloads, like cleavable and non-cleavable linkers.
Based on Nona’s deep understanding of ADC molecules, we perform a comprehensive assessment of molecules for lead identification and characterization, including DAR determination, conjugation stability, plasma stability and drug-releasing efficiency.
A full range of in vitro bioactivity studies for both monoclonal antibodies and ADCs is available, including antigen binding, internalization, soluble antigen interference, cytotoxicity, and bystander killing. Nona also encompasses integral capabilities for in vivo studies, including various pharmacological models for ADC efficacy assessment, such as CDX, PDX, and heterogeneous tumor models. Additionally, pre-toxicity evaluation and small animal PK studies complete the integrated ADC R&D services.
Lorem ipsum dolor sit amet consectetur. Quis ultricies accumsan aliquet pulvinar leo magnis sit porttitor. Habitant venenatis risus.
Lorem ipsum dolor sit amet consectetur. Viverra sed arcu elementum integer adipiscing. Egestas lorem vitae elit malesuada luctus enim justo enim vestibulum. Consectetur malesuada sit feugiat quam quam consequat bibendum aliquam dictum. Ullamcorper volutpat a commodo ornare vitae tortor gravida. Massa massa metus senectus ac sit fermentum nunc nulla. Gravida gravida iaculis potenti ut quam.
Beacon® single B cell screening
Display technology
CAR-function based functional screening
Hybridoma
HCAb direct cloning screening
TCR Mimic Antibody
Functional characterization
Binding / Affinity
Antibody production
In vitro functional assay
Developability
Protein
Cell line
DNA
mRNA
Target assessment
Recombinant protein
Recombinant cell-line
Affinity maturation ▶
Humanization▶
Fc-Engineering▶
Structure-Based Protein Design
▶
Stable cell line
Process development
Manufacture
PK / PD
Efficacy
ADA
TOX
Dr. Jingsong Wang is Chairman of Nona Biosciences. Prior to that, Dr. Wang served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D. in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher’s laboratory at the Harvard School of Public Health.
Dr. Yiping Rong is our Chief Scientific Officer. He is a well-recognized scientist with about 20 years’ experience of biomedical research and drug discovery. Dr. Rong used to work at Sanofi, JNJ and Roche and built strong expertise in cancer biology and pharmacology. He led and contributed to >15 programs entering clinical trials. He is also involved in translational research work for a few drugs. Multiple mAb or bispecific antibodies generated from his team were out licensed to MNCs. Some highly innovative first-in-class projects are in clinical trials. He worked on apoptosis, epigenetics, immuno-oncology, and cancer cell signaling fields and led the drug discovery projects including kinase, enzyme, receptor/ligand, protein-protein-interaction targets by small molecules or monoclonal antibodies. Dr. Rong received his Ph.D. degree in Pharmacology from Case Western Reserve University (Cleveland, Ohio). He is the member of American Association of Cancer Research and has more than twenty publications in cancer research field, including Nature Genetics, Molecular Cell, PNAS papers. He is also the inventor of dozens of patents in drug discovery field.
Dr. Jiyong Zhang leads business development at Nona Biosciences, bringing vision and dedication to strategic growth and client satisfaction. With 15 years of experience in biotherapeutic research and development, Dr. Zhang’s understanding of market dynamics and ability to identify mission-aligned opportunities are evident.
Before overseeing business development at Nona, Dr. Zhang played key roles at Alexion and Abbvie, contributing to antibody discovery, engineering, and bispecific antibody R&D. His scientific experiences and knowledge in biotherapeutic innovation makes him a forward-thinking strategist focused on enhancing service offerings to meet evolving client needs.
With Dr. Zhang and his team driving business development, Nona Biosciences is poised to offer innovative solutions and unparalleled service. This solidifies the company’s position as a trusted and client-focused drug discovery partner in the dynamic landscape of biotherapeutic innovation.
Dr. Joe Zhao is Vice President and Head of External Innovation of Nona Biosciences. Joe holds a BS from Fudan University and a PhD from University of Delaware, followed by postdoctoral trainings at Lankenau Medical Center and Zeneca Pharmaceuticals. Prior to joining Harbour BioMed, he was in small biotechs (Pharmacopeia and Ligand Pharmaceuticals) and large MNC (BMS). Joe has 25 years of combined experience in drug discovery of both small molecules and biologics in therapeutic areas of immuno-oncology, immunology, and genetic diseases.
Mr. Louis Liu is Senior Vice President and Head of Scientific Operation of Nona Biosciences. He graduated from Bethune Medical University with Bachelor Degree of Medicine. He has over 30 years’ experience in antibody technology platform establishment, antibody discovery and discovery team management experience. Previously he worked in Syntron Bioresearch Inc as R&D manager, Strategic Diagnostic Inc as product development supervisor, Rockland Immunochemical Inc as Manager of Monoclonal Antibody service and product development, GenScript Ltd as vice president of Antibody Division, Shanghai ChemPartner as vice president of Biologics Discovery.
Dr. Yun He is Chief Technology Officer of Nona Biosciences. Before Nona Biosciences spun off from Harbour BioMed, Dr. He served as Head of Antibody Technology at Harbour BioMed. During his tenure there, Dr. He contributed to multiple discovery programs and led the team in establishing HBICE® platform. Prior to joining Harbour BioMed, Dr. He was an Investigator at Biologics Center in Novartis, where he was responsible for antibody engineering and bioinformatics. Prior to that, Dr. He was the group leader of Bioinformatics at GenScript. Dr. He received his Ph.D. from the Chinese Academy of Sciences, with a focus on molecular biology and bioinformatics.
Dr. Musheng Bao earned his Ph.D. in China and completed his postdoctoral training at MD Anderson Cancer Center and Baylor Institute for Immunology Research. Beginning his professional journey as a Scientist II at MedImmune, Dr. Bao later transitioned to Sanofi, where he served as a Principal Scientist. Following this, he joined Harbour BioMed, where he led a team dedicated to therapeutic antibody development utilizing the Harbour Mice® platform. Presently, Dr. Bao has taken on the role of Head of Biology at Nona Biosciences.
Dr. Arkinstall has demonstrated remarkable competence throughout his career. He is a respected leader in drug discovery with substantial roles under his belt, including Research Head, Chief Scientific Officer (CSO), and Chief Executive Officer (CEO) positions at various pharmaceutical or biotech companies. Dr. Arkinstall served as CEO of Elstar Therapeutics and Revitope Oncology, companies advancing novel classes of multi-specific antibody-based cancer drugs. He previously was also the CSO of Kymab, an antibody therapeutics company founded in Cambridge, UK, prior to which he spent 16 years in progressively senior research leadership roles at EMD (Merck) Serono, and its associated entities across Europe and the United States.
Dr. Grosveld is Co-founder and CSO of Harbour Antibodies and the inventor of Harbour Mice®, Professor and former Head of Department of Cell Biology and Department of Clinical Genetics at Erasmus University Medical Center, Rotterdam, a fellow of Royal Society and a member of Royal Netherlands Academy of Arts and Sciences. Dr. Grosveld’s research on the control of globin gene expression has been selected as one of the top ten achievements of Medical Research Council (UK) (MRC) in the 20th century by Higher Education and Research Opportunities in the U.K. Dr. Grosveld was awarded the Louis-Jeantet Prize for Medicine in 1991, the Spinozapremie (Spinoza Prize) in 1995.
Dr. Kamen is a Venture Partner at Third Rock Ventures. In 2005, he co-founded BioAssets Development Corporation and served as its Chairman. He currently serves as an independent non-executive Director of Harbour BioMed and a director of Jounce Therapeutics (NASDAQ:JNCE). He was previously a director of Neon Therapeutics and Harbour Antibodies. Earlier in his career, he was senior vice president of scientific affairs at the pioneering biotechnology firm named Genetics Institute, Inc. Dr. Kamen received his bachelor’s degree in biophysics from Amherst College, a Ph.D. in biochemistry and molecular biology from Harvard University Graduate School of Arts and Sciences. During his academic scientific career, he worked at the Imperial Cancer Research Fund.
Dr. Kramer serves as CSO of Portage Biotech Inc. Dr. Kramer previously served as Vice President and Head of Discovery for Oncology Therapeutics at Janssen Research & Development, LLC (the Pharmaceutical Division of Johnson and Johnson), where he was responsible for leading Global Discovery, focusing on aberrant signaling cascades in tumor cells, as well as epigenetic reprogramming and tumor immunology using both small molecule and protein-based large molecule approaches. Prior to joining Janssen Research & Development, LLC, Dr. Kramer served as VP Drug Discovery and Research for Bristol-Myers Squibb (BMS), where he provided scientific leadership and strategic oversight for many pre-clinical Oncology and Immunology programs and projects that entered development. Dr. Kramer was previously an Assistant Professor at Harvard Medical School. Dr. Kramer received his Ph.D. in pharmacology from the University of Vermont and completed his post-doctoral fellowship in Oncology at the National Cancer Institute, National Institutes of Health.
Peter Moesta, Ph.D., oversaw the development, production and worldwide launch of important medicines, such as Humira, Yervoy and Opdivo. Dr. Moesta previously served in executive roles at Bristol-Myers Squibb.
Dr. Tian is an academician of Chinese Academy of Engineering, a member of Academia Europaea and a medical immunologist. Currently, he is a professor at University of Science and Technology of China (USTC), where he also works as Dean at School of Basic Medical Sciences, and Director at Institute of Immunology. He is also the Director of the Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science.
Dr. Tian was awarded with the National Science Fund for Distinguished Young Scholars. He is the academic leader of Chang Jiang Scholars Program as well as the Innovation Research Program of National Natural Science Foundation of China. Dr. Tian is Head of National Science and Technology Major Project and Chief Scientist of National Major Research Plan Program.
Dr. Tian’s laboratory is credited with seminal discoveries regarding basic knowledge and clinical study of natural killer (NK) cells, particularly liver-resident NK cells, cytokine-producing NK cells, and NK cell-based immunotherapy.
